<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01837849</url>
  </required_header>
  <id_info>
    <org_study_id>AHNTU-2010-28</org_study_id>
    <nct_id>NCT01837849</nct_id>
  </id_info>
  <brief_title>A Comparison of Recombinant Human Brain Natriuretic Peptide and Dobutamine</brief_title>
  <official_title>Comparative Effects of Recombinant Human Brain Natriuretic Peptide and Dobutamine on Acute Decompensated Heart Failure Patients With Different Blood BNP Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the therapeutic efficacy of recombinant human brain natriuretic peptide (rhBNP)
      with dobutamine on acute decompensated heart failure patients with different blood BNP levels
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with acute decompensated heart failure (ADHF) whose left ventricular ejection
      fraction(LVEF) was &lt;40%, were assigned to a high BNP group (BNP â‰¤ 3000 pg/mL) or an
      extra-high BNP group (BNP &gt; 3000 pg/mL) , depending on their admission plasma BNP levels.
      Each group was then subdivided into rhBNP or dobutamine subgroups according to intravenous
      administration with either rhBNP or dobutamine for 24-72h. The effects of rhBNP and
      dobutamine on patients in the high and extra-high BNP groups were compared.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>left ventricular ejection fraction (LVEF) in the High and Extra-high BNP Groups</measure>
    <time_frame>baseline and 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricle end diastolic dimension (LVEDD)in the High and Extra-high BNP Groups</measure>
    <time_frame>baseline and 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood BNP in the High and Extra-high BNP Groups</measure>
    <time_frame>baseline and 5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in New York Heart Association (NYHA) Class from Baseline to Day 5 after Treatment</measure>
    <time_frame>baseline and 5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure (mmHg)</measure>
    <time_frame>baseline and 5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>baseline and 5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Creatinine</measure>
    <time_frame>baseline and 5 days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">104</enrollment>
  <condition>Acute Decompensated Heart Failure</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with acute decompensated heart failure who required hospitalization
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients were classified as NYHA class III-IV

          -  ejection fraction &lt;40%

        Exclusion Criteria:

          -  intravenous administration with rhBNP or dobutamine in the 2 weeks before study entry

          -  acute myocardial infarction

          -  significant valvular stenosis

          -  serious ventricular arrhythmia (frequent ventricular premature beat of &gt;5 bpm,
             nonsustained and sustained ventricular tachycardia)

          -  blood pressure &lt;95/60 mmHg or &gt;140/90 mmHg

          -  shock

          -  hypovolemia

          -  hepatic or renal impairment

          -  pregnant and lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianhua Zhu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nantong University</affiliation>
  </overall_official>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2013</study_first_submitted>
  <study_first_submitted_qc>April 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2013</study_first_posted>
  <last_update_submitted>April 18, 2013</last_update_submitted>
  <last_update_submitted_qc>April 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nantong University</investigator_affiliation>
    <investigator_full_name>Haiyan PAN</investigator_full_name>
    <investigator_title>associate chief physician</investigator_title>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>rhBNP</keyword>
  <keyword>Dobutamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dobutamine</mesh_term>
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

